Jim Simons
PCSA icon

Jim Simons’s Processa Pharmaceuticals PCSA Stock Holding History

Jim Simons’s Portfolio PCSA Stock Details PCSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-116
Closed -$19K – 3977
2023
Q4 		$19K Buy
116
+8
+7% +$1.78K ﹤0.01% 3584
2023
Q3 		$13K Buy
108
+17
+19% +$3.21K ﹤0.01% 3565
2023
Q2 		$23K Buy
91
+29
+47% +$8.57K ﹤0.01% 3746
2023
Q1 		$16K Buy
62
+34
+121% +$13.7K ﹤0.01% 3849
2022
Q4 		$16K Buy
28
+5
+22% +$4.83K ﹤0.01% 3994
2022
Q3 		$26K Hold
23
– – ﹤0.01% 3864
2022
Q2 		$33K Buy
+23
New +$31.5K ﹤0.01% 4063

Other funds holding PCSA

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
MSG
Main Street Group Glen Allen, Virginia $429M AUM 34.03% 1-Year Est. Return
AF
Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return
MIM
Macroview Investment Management Bethesda, Maryland $162M AUM 22.52% 1-Year Est. Return

Jim Simons's PCSA Position: Q1 2024 in Review

Jim Simons sold out of Processa Pharmaceuticals (PCSA) in Q1 2024, closing a stake of 116 shares — an estimated $19K sold.

Jim Simons first reported a position in PCSA in Q2 2022 and held it in 7 quarters. The position peaked at $33K in Q2 2022. 9 funds tracked by Wall St. Rank hold PCSA as of Q1 2024.

  • Jim Simons reported no remaining Processa Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Jim Simons sold 116 Processa Pharmaceuticals shares in Q1 2024, an estimated $19K.
  • Jim Simons first reported a position in Processa Pharmaceuticals in Q2 2022 and held it in 7 quarters.
  • Jim Simons's Processa Pharmaceuticals position peaked at $33K in Q2 2022.
  • 9 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q1 2024.

Based on Renaissance Technologies's 13F filing for Q1 2024, filed 13 May 2024.